EXT418, a novel long‐acting ghrelin, mitigates Lewis lung carcinoma induced cachexia in mice
Abstract
Ghrelin is a potential therapy for cachexia due to its orexigenic properties and anabolic effects on muscle and fat. However, its clinical use is limited by the short half‐life of active (acylated) ghrelin (~11 min in humans). EXT418 is a novel long‐acting, constitutively active ghrelin analog created by covalently linking it to a vitamin D derivative. Here, we evaluated the effects and mechanisms of action of EXT418 on Lewis lung carcinoma (LLC)‐induced cachexia in mice.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 21, 2023
- Source ID
- 10.1002/jcsm.13211
Entities
People
- Alice (siyi) Jiang
- Amanda Chen
- Anthony Christiani
- Artur Rybachok
- Barbara Anderson
- Beatrice A. Breckheimer
- Brynn Irwin
- Caroline H. Kostyla
- Daniel B. Hall
- Elizabeth Dacek
- Haiming M Liu
- Ian (in‐gi) Lee
- José M. Garcia
- Kora Krumm
- Laura M. Hales
- Lena Strait
- Lucas Caeiro
- Tarik M. Soliman
Organizations
- Congressionally Directed Medical Research Programs
- United States Department of Veterans Affairs
- University of Washington